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Understanding the metabolic factors that contribute to energy metabolism (EM) is critical
for the development of new treatments for obesity and related diseases. Mitochondrial
oxidative phosphorylation is not perfectly coupled to ATP synthesis, and the process of
proton-leak plays a crucial role. Proton-leak accounts for a significant part of the resting
metabolic rate (RMR) and therefore enhancement of this process represents a potential
target for obesity treatment. Since their discovery, uncoupling proteins have stimulated
great interest due to their involvement in mitochondrial-inducible proton-leak. Despite the
widely accepted uncoupling/thermogenic effect of uncoupling protein one (UCP1), which
was the first in this family to be discovered, the reactions catalyzed by its homolog UCP3
and the physiological role remain under debate. This review provides an overview of the
role played by UCP1 and UCP3 in mitochondrial uncoupling/functionality as well as EM and
suggests that they are a potential therapeutic target for treating obesity and its related
diseases such as type II diabetes mellitus.
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INTRODUCTION
Mitochondria are the major regulators of cellular energy
metabolism (EM). Alterations of mitochondrial functionality
have been linked to the pathogenesis of somemetabolic disorders,
including obesity and type II diabetes mellitus (T2DM).
The principal function of mitochondria is ATP production.
Reduced cofactors, such as NADH and FADH2, obtained from
oxidizable molecules (carbohydrates, lipids, and proteins) sup-
ply electrons to the electron transport chain (ETC) and result in
a final reduction of molecular oxygen to water. Electron trans-
fer through the ETC controls pumping of protons (H+) from
the matrix to the intermembrane space, thus creating a proton-
motive force (p), whose energy is used by ATP synthase for the
phosphorylation of ADP.
Mitochondrial oxidative phosphorylation is not perfectly cou-
pled to ATP synthesis, since a portion of the energy liber-
ated from the oxidation of dietary energy substrates is lost as
heat instead of being converted into ATP. Indeed, some of the
energy present in p dissipates as heat by the re-entry of H+
into the matrix, through pathways independent of ATP syn-
thase (proton-leak). Proton-leak is the sum of two processes:
basal- and inducible proton-leak (Brand and Esteves, 2005). The
first is not acutely regulated, but rather depends on the fatty-
acyl composition of the mitochondrial inner membrane and
the presence of adenine nucleotide translocase. On the other
hand, inducible proton-leak is acutely controlled, with uncou-
pling proteins playing a crucial role (Divakaruni and Brand, 2011)
(Figure 1).
Proton-leak has a marked influence on the entire EM of an
organism, and, in rats, accounts for approximately 20–30% of the
resting metabolic rate (RMR) (Rolfe and Brand, 1996). Variations
in the proton-leak process contribute to the development of
obesity or weight loss (Harper et al., 2008), and thus there
has been increasing interest in targeting this process in order
to increase RMR to treat obesity and other related diseases
(Figure 1).
The present review discusses the relevance of UCPs on influ-
encing EM. In particular, it focuses on uncoupling protein one
(UCP1) andUCP3 due to their expression in brown adipose tissue
(BAT) and skeletal muscle (SkM), respectively, which significantly
contributes to EM.
UNCOUPLING PROTEIN-1 (UCP1)
UCPs are members of the mitochondrial anion carrier family.
The first uncoupling protein identified, UCP1, is predominantly
expressed in BAT where it represents approximately 10% of
the mitochondrial protein content and plays a thermogenic role
through the catalysis of proton-leak. Recent evidence indicates
the existence of two types of thermogenic adipocytes express-
ing UCP1: the classical brown adipocytes, which are found
in the intercapsular brown adipose organ, and beige/bright
adipocytes, which are found in subcutaneous WAT. Only recently
it has unequivocally been proven that UCP1-positive cells found
in WAT (i.e., beige adipocytes) are thermogenic-competent
(Shabalina et al., 2013) and are actually a distinct subpopula-
tion of white adipocytes that originate from a different lineage
(reviewed in Harms and Seale, 2013).
One of the most prominent differences between brown and
beige adipocytes is that brown cells express high levels of UCP1
and other thermogenic genes under basal (unstimulated) con-
ditions, whereas beige adipocytes only express these genes in
response to activators, such as β-adrenergic and peroxisome
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FIGURE 1 | Schematic representation of proton-leak and of the proposed role of UCPs in influencing energy metabolism.
proliferator-activated receptor-γ agonists (Petrovic et al., 2010;
Wu et al., 2013; Carrière et al., 2014). Nevertheless, both
adipocyte types show comparable levels of UCP1 upon stimula-
tion, indicating that under specific conditions they may have the
same thermogenic capacity (Wu et al., 2012).
Cold and overfeeding are physiological stimuli that influ-
ence BAT thermogenesis through the enhancement of sympa-
thetic overflow to BAT (Cannon and Nedergard, 2004). Acute
sympathetic nerve activation stimulates heat production by acti-
vating UCP1 function. Indeed, noradrenergic stimulation of
brown adipocytes activates cAMP-linked signaling pathways,
which results in increased (i) mitochondria number and size, (ii)
UCP1 gene transcription and translation, and (iii) UCP1 thermo-
genic activity through activation of lipolysis and release of acute
regulators of UCP1, such as free fatty acids.
Prolonged cold exposure stimulates the proliferation and
differentiation of brown precursor cells to expand BAT mass
and increase thermogenic capacity (Bukowiecki et al., 1982).
Moreover, it also induces beige adipocyte development and func-
tion (Vitali et al., 2012). Although sympathetic nerve activity
was previously thought to be the major physiological signal that
activates BAT thermogenesis and induces beige adipocyte devel-
opment, numerous hormones and factors have now been shown
to regulate such processes. Moreover, brown and beige adipocytes
can be selectively recruited and activated (for review Cannon and
Nedergard, 2004; Harms and Seale, 2013). The molecular mecha-
nisms of UCP1 activation have been comprehensively discussed
in other recent reviews and will not be elaborated upon here
(Klingenberg and Echtay, 2001; Porter, 2008).
ROLE OF UCP1 IN ENERGY METABOLISM
The presence of UCP1 provides a marked capacity for BAT to
dissipate energy by as much as 20%. In rodents, overeating
activates BAT “diet-induced thermogenesis,” that preserve energy
balance and contrasts obesity by reducing metabolic efficiency
(Cannon and Nedergard, 2004). The overexpression of UCP1
or activation of BAT thermogenesis has been shown to prevent
the development of obesity (Krauss et al., 2005). In contrast,
the first experiments performed on UCP−/−1 mice housed at
a standard temperature (20–22◦C) failed to show an enhanced
obesity predisposition compared to their wild-type counterparts
(Enerback et al., 1997). More recently, Feldmann et al. (2009)
reported that UCP1 ablation induced obesity in mice housed at
30◦C, i.e., the thermoneutral temperature at which mice faculta-
tive thermogenesis is kept at a minimum. Indeed, when housed at
20–22◦C, mice are under chronic thermal stress and inevitably
increase their metabolic rate (∼50%) to maintain body tem-
perature (Golozoubova et al., 2006). Therefore, UCP−/−1 mice,
that are unable to enhance BAT thermogenesis, have necessar-
ily expend extra energy to defend their body temperature; the
activation of alternative compensatory mechanisms, such as shiv-
ering thermogenesis, could have masked the role of UCP1 on EM.
The study of Feldmann et al. (2009) also suggests that the impact
of housing temperature on EM has been overlooked by most of
the studies on animal models, and that cold stress could have
confounded many studies. Humans tend to live at thermoneu-
trality, with the aid of clothing and heating. Thus, to translate
the metabolic studies performed in mice to humans, experiments
should be conducted under thermoneutral conditions.
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Other evidence also support the role for UCP1 in EM. For
example, transgenic mice expressing UCP1 in white fat depots
display a lean phenotype (reviewed in Klaus et al., 2012).
Moreover, muscle-specific ectopic expression of UCP1 leads to
increased energy expenditure, delayed diet-induced obesity devel-
opment, improved glucose homeostasis, increased insulin stim-
ulated glucose uptake, and increased lipid metabolism (Keipert
et al., 2013; Ost et al., 2014). This is in agreement with evidence
showing that the selective induction of SkM UCP1-mediated
proton-leak leads to an increased whole body energy expenditure
as well as decreased adiposity (Adjeitey et al., 2013).
When chronically activated by cold exposure, UCP1 mediated-
BAT thermogenesis enhances the oxidation of metabolic sub-
strates necessary for sustaining enhanced thermogenesis. Under
these conditions, BAT not only use stored lipids as substrates,
but also large quantities of glucose and triglycerides (the last
mainly in the form of chylomicrons) from the circulation (Bartelt
et al., 2012; Peirce and Vidal-Puig, 2013). Therefore, by decreasing
plasma lipids, lowering plasma glucose, and diminishing obesity,
BAT has a potential role in protecting against obesity and T2DM.
UCP1 EXPRESSING ADIPOCYTES ARE PRESENT IN ADULT
HUMAN
It was previously thought that in humans, BAT disap-
pears rapidly after birth. However, more recently the use
of radiodiagnostic techniques [positron emission tomography
(PET)/computed tomography (CT)] together with histological
methods has unequivocally identified the presence of UCP1-
expressing adipocyte depots in adult humans. The tissue is not
present in defined regions, but rather scattered within the WAT
(Nedergaard et al., 2007). However, it is currently unclear whether
the deposits of UCP1-expressing adipocytes in adult humans are
analogous to beige or brown fat.
The enhancement of BAT activity or the browning of WAT
in humans has been linked to cold tolerance, enhanced energy
expenditure, and protection against metabolic diseases, such as
obesity and T2DM (for review Harms and Seale, 2013; Saito,
2013). In fact, the amount of metabolic active BAT in humans
positively correlates with RMR and inversely with body mass
index (BMI), fat mass (van Marken Lichtenbelt et al., 2009), and
the development of T2DM. In addition, it has been shown that
genetic variants of UCP1 are associated with fat metabolism, obe-
sity, and diabetes. Among the UCP1 polymorphisms, the A3826G
SNP in the promoter region has been associated with obesity,
weight gain, and resistance to weight loss (reviewed in Jia et al.,
2010).
UNCOUPLING PROTEIN-3 (UCP3)
UCP3 is primarily expressed in skeletal muscle, but it is also found
in BAT and heart tissue. Although UCP3 was first discovered and
described in 1997 (Boss et al., 1997), the mechanisms of activa-
tion as well as its physiological role is still under debate (Cioffi
et al., 2009). Due to its close homology with UCP1, UCP3 was
initially implicated in thermoregulation (Boss et al., 1997), as
it has been demonstrated to uncouple in a number of exper-
imental models. However, other evidence has questioned the
uncoupling activity of UCP3, including findings that (i) higher
expression of UCP3 is not always associated with increased mito-
chondrial uncoupling (such as during fasting Cadenas et al.,
1999) and (ii) UCP−/−3 mice do not show thermoregulation prob-
lems and are not obese (Gong et al., 2000; Vidal-Puig et al., 2000).
Indeed, UCP3 mediated-uncoupling (called mild uncoupling)
seems to be activated by specific cofactors, with FFA and reac-
tive oxygen species (ROS) playing crucial and interrelated roles
(Brand and Esteves, 2005; Lombardi et al., 2008, 2010), being the
absence of one on these cofactors able to musk UCP3-mediated
uncoupling.
UCP3 is also thought to play key regulatory roles in mito-
chondrial fatty acid oxidation and in preventing mitochondrial
ROS-induced oxidative damage (Cioffi et al., 2009). Regarding
the former, studies relating to the enhancement in SkM UCP3
expression have provided evidence for a close relationship to sit-
uations in which there is increased fatty acid oxidation (reviewed
in Bezaire et al., 2007; Cioffi et al., 2009). SkM mitochondria
isolated from UCP−/−3 mice have a lower ability to oxidize fatty
acids than those fromUCP+/+3 mice (Costford et al., 2008; Senese
et al., 2011), that plausibly is responsible for the greater fat stor-
age observed following long-term high fat feeding in mice lacking
UCP3 (Nabben et al., 2011).
UCP3 also plays an important role in protecting cells
against oxidative damage (Brand and Esteves, 2005; Goglia and
Skulachev, 2003; Nabben et al., 2008; Schrauwen and Hesselink,
2004b). UCP3 may aid in mitigating ROS emission from the
ETC; this role seems to be related to UCP3-mediated uncoupling
and the consequent reduction in p. In fact, p is a key fac-
tor in influencing mitochondrial O2− release (Korshunov et al.,
1997) and a slight reduction in p is associated to a signifi-
cant depression of O2− release. Interestingly, ROS itself or ROS
by-products can induce UCP3 uncoupling, which provides a neg-
ative feedback loop for mitochondrial ROS production (Brand
and Esteves, 2005). The sequential molecular mechanisms under-
lying ROS induced- and UCP3-mediated uncoupling seems to
involve glutathionylation of the protein: a slight increase in ROS
production promotes UCP3 de-glutathionylation, which activates
UCP3-mediated uncoupling and further decreases ROS emission
(Mailloux et al., 2011).
Another hypothesis concerning the role of UCP3 in protect-
ing mitochondria from oxidative damage suggests that UCP3
is involved in the export of LOOH, which accumulates on the
matrix side of the mitochondrial inner membrane (MIM), out
of the matrix. This mechanism would reduce or eliminate LOOH
from the inner leaflet of the MIM, which could otherwise trig-
ger a cascade of oxidative damage to mitochondrial DNA and
enzymes as well as other critical mitochondrial matrix-localized
components (Goglia and Skulachev, 2003). This hypothesis has
been validated by studies onmitochondria isolated fromUCP+/+3
and UCP−/−3 mice, which underscores the ability of UCP3 to
translocate LOOH andmediate LOOH-dependent mitochondrial
uncoupling (Lombardi et al., 2010).
ROLE OF UCP3 IN ENERGY METABOLISM
Many studies have demonstrated that mitochondrial function-
ality is compromised in obesity and T2DM. In skeletal muscle,
www.frontiersin.org February 2015 | Volume 6 | Article 36 | 3
Busiello et al. UCPs and metabolism
decreased mitochondrial uncoupling together with impaired
mitochondrial fatty acid oxidation lead to fatty acids and/or
their metabolites accumulation which, associated to increased
oxidative stress, are crucial aspects in the development and pro-
gression of the above pathologies (Goodpaster et al., 2001; Patti
and Corvera, 2010). Indeed, states of insulin-resistance are char-
acterized by increased LOOH levels in SkM, and patients with
T2DM exhibit damaged mitochondria with reduced functional
capacity.
The involvement of UCP3 in mild uncoupling, in protection
from ROS- and/or LOOH-induced oxidative stress, and in the
amelioration of the fatty acid oxidation rate (see above) suggest
a protective role for this protein in obesity and T2DM (Figure 2).
This possibility is strengthened by findings that UCP3 is expressed
in SkM, which is a tissue that represents 40% of metabolic active
mass and largely contributes to energy homeostasis.
More experimental evidence supports a role of UCP3 in EM,
including the findings that (i) UCP3 transgenic mice are less
efficient in metabolism than wild-type controls (Costford et al.,
2006) and are protected against high fat diet-induced obesity
(Son et al., 2004; Costford et al., 2006); (ii) an enhancement of
SkM UCP3 levels (also associated with higher BAT UCP1 lev-
els) has been observed in obesity-resistant mice compared to
obesity-prone mice (Fink et al., 2007); and (iii) modest UCP3
overexpression in skeletal muscle mimics physical exercise by
increasing spontaneous activity and energy expenditure in mice
(Aguer et al., 2013). Conversely, studies performed on UCP−/−3
mice argue against a role for UCP3 in EM, since these mice
do not present reduced RMR and are not obese (Vidal-Puig
et al., 2000). However, these studies were performed in mice
housed at 20–22◦C, a condition that, as described above, repre-
sents chronic thermal stress [see Uncoupling Protein-1 (UCP1)
section]. Therefore, the occurrence of compensatory thermogenic
mechanisms in UCP−/−3 mice could havemasked the possible role
of the protein in EM.
UCP3 also shows a protective role in T2DM. However, when
studies were performed on transgenic mice, a clear involvement
of the protein was evident when UCP3 overexpressing animals
were used as a model (Choi et al., 2007; Costford et al., 2008).
Instead, in UCP−/−3 fed a high fat diet regimen (known to induce
a state of insulin resistance), insulin sensitivity has been reported
to be unaffected (Vidal-Puig et al., 2000), enhanced (Costford
et al., 2008), or reduced (Costford et al., 2008; Senese et al.,
2011), with the effect being dependent on the age of the mice.
Costford et al. (2008). On the other hand, UCP3+/− heterozy-
gous mice show an approximate 50% reduction in SkM UCP3
protein levels when compared to UCP3+/+, and a clear decline
in insulin sensitivity has been reported. The effect was observed
both when mice were fed with a standard diet or with a high
fat diet (Senese et al., 2011). These data are in good accordance
with clinical observations reporting that (i) a 50% reduction of
UCP3 protein in human SkM is correlated with the incidence
of T2DM (Schrauwen et al., 2001); and (ii) in humans, UCP3
protein levels are reduced in the pre-diabetic state of impaired
FIGURE 2 | Schematic diagram that illustrates how the reactions influenced by UCP3 could be redirected to prevent or treat obesity, insulin
resistance, and type 2 diabetes (T2DM).
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glucose tolerance (Schrauwen and Hesselink, 2004a; Mensink
et al., 2007).
Human Polymorphisms in the UCP3 gene also suggest an
impact of UCP3 on fat metabolism, obesity, and T2DM. In this
context, the UCP3 gene polymorphism –55T allele has been
linked to enhanced UCP3 mRNA expression and RM (Schrauwen
et al., 1999). Heterozygous C/T is associated with decreased obe-
sity and T2DM risk (Meirhaeghe et al., 2000; Herrmann et al.,
2003; Liu et al., 2005). Importantly, these findings have been
recently confirmed through a meta-analysis showing an asso-
ciation of the polymorphism with protection from obesity in
a European patient population (de Almeida Brondani et al.,
2014). The association between the −55CT polymorphism of
UCP3 and a lower BMI, however, is modulated by energy intake,
since it disappears when caloric intake is increased (Lapice et al.,
2014).
Heterozygous individuals that have a missense G304A poly-
morphism show decreased whole body fat oxidation compared to
controls (Argyropoulos et al., 1998). They also present reduced
levels of plasma lactate (Adams et al., 2009), that can be plausi-
bly due to an impaired consumption of long chain fatty acids for
muscle energy and to a greater reliance upon carbohydrates for
energy.
Recently, four novel and heterozygous mutations in the UCP3
gene were identified (V56M, A111V, V192I, and Q252X) (Musa
et al., 2012). Children carrying these mutations exhibited a higher
percentage of fat and BMI, which was associated with dyslipi-
demia and lower insulin sensitivity (Musa et al., 2012).
CONCLUDING REMARKS AND PERSPECTIVE
Targeting processes that lead to a reduction in mitochondrial
coupling/efficiency and ROS production (thus oxidative stress)
could be a promising therapeutic strategy to combat obe-
sity and its co-morbidities (such as T2DM). The uncoupling
proteins have several hypothesized functions including ther-
mogenesis in certain tissues, protection from ROS, mediation
of fatty acids oxidation and export of fatty acids, which are
all related to the above pathologies. Hence, an understand-
ing of the mitochondrial processes that lead to uncoupling
and, in particular, the elucidation of the exact role played by
UCPs at the mitochondrial level and in EM may provide an
attractive therapeutic target for diseases rooted in metabolic
imbalance.
In this context, the recruitment of thermogenic brown and/or
beige adipocytes through activation of UCP1, and by expanding
the tissue, through drugs or other methods, provide a promising
approach for enhancing energy expenditure and combating obe-
sity comorbidities. Recent evidence, indicating that brown and
beige adipocyte can be recruited by different stimuli, raises the
possibility that they may represent separate and distinct targets
for therapeutic intervention. Although the roles of UCP3 are not
completely clear, current data in human subjects (living at ther-
moneutrality) suggest a possible involvement of this protein in
EM as well as in counteracting obesity, insulin resistance, and
T2DM (Figure 2). Therefore, UCP1 and UCP3 represent promis-
ing therapeutic targets for treating pathologies that result from
energy unbalance.
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